芪参益气滴丸联合心脉通贴散对PCI术后患者临床疗效及炎症因子的影响  

Clinical Effect of Qishen Yiqi Pills Combined with Xinmai Tongtie Powder on Post-PCI Patients and Inflammatory Factors

作　　者：刘敏[1,2] 张培影[3] 王忠良[1,2] 梁田[1,2] 卢磊[1,2] 张庆 夏伟[4,5] 王娟[3] LIU Min;ZHANG Pei-ying;WANG Zhong-liang;LIANG Tian;LU Lei;ZHANG Qing;XIA Wei;WANG Juan(First Clinical Medical College,Nanjing University of Chinese Medicine,Nangjing（210023;Department of Cardiology,Affiliated Xuzhou Hospital of Nanjing University of Chinese Medicine,Xuzhou City Hospital of Traditional Chinese Medicine,Jiangsu（221003;Department of Cardiology,Xuzhou Center Hospital,Jiangsu（221009;Department of Geriatrics,Jian-gsu Province on Intergrationg of Chinese and Western Medicine,Nanjing（210028)

机构地区：[1]南京中医药大学第一临床医学院,南京210023 [2]南京中医药大学附属徐州医院徐州市中医院心血管科,江苏221003 [3]江苏省徐州市中心医院心血管科,江苏221009 [4]江苏省中西医结合医院老年科,南京210028 [5]南京市江宁医院老年科,南京211100

出　　处：《中国中西医结合杂志》2018年第9期1049-1053,共5页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：徐州市科技支撑计划(No.社会发展项目:KC16SH044)

摘　　要：目的观察芪参益气滴丸联合心脉通贴散对经皮冠脉介入治疗(PCI)术后患者生活质量、凝血功能、超敏-C反应蛋白(hs-CRP)、髓过氧化物酶(MPO)的影响。方法选择160例行PCI术的心绞痛患者,采用随机数字表法分为对照组和治疗A、B、C组,每组40例。四组均采用常规西药治疗,治疗A组在此基础上加用心脉通贴散;治疗B组在此基础上加用芪参益气滴丸;治疗C组在此基础上加用芪参益气滴丸及心脉通贴散贴敷,疗程均为4周。观察患者西雅图心绞痛量表[包括躯体活动受限程度(PL)、心绞痛稳定状态(AS)、心绞痛发作情况(AF)、治疗满意程度(TS)、疾病认知程度(DP)]、凝血功能[包括凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)]、hs-CRP和MPO水平变化。结果与本组治疗前比较,各组治疗后PL、AS、AF、TS、DP评分升高,血FIB、血hs-CRP和MPO水平降低(均P<0.05),PT、APTT、TT均有不同程度延长,但差异无统计学意义(P>0.05);与对照组同期比较,治疗后治疗各组PL、AS、AF、TS、DP评分均升高(P<0.05),FIB、血hs-CRP和MPO水平降低(P<0.05),且治疗C组优于治疗A、B组(P<0.05)。结论芪参益气滴丸联合心脉通贴散可以改善PCI术后患者的生活质量,改善凝血功能,降低炎症因子(hs-CRP、MPO)水平。Objective To explore the effect of Qishen Yiqi Pills （QSYQP） combined with Xinmai Tongtie Powder （XTP） on patient＇s quality of life, coagulation function high sensitive C-reactive protein （hs- CRP） level and myeloperoxidase （MPO） level after percutaneous coronary intervention （PCI）. Methods To- tally 160 PCI patients were assigned to 4 groups, namely the control group, group A, group B and group C, according to the random digit table, 40 cases in each group. All patients received routine Western medi- cine, but with the combination of XTP for group A, QSYQP for group B and both XTP and ASYQP for group C. All medication lasted for 4 successive weeks. Then via the Seattle Angina Questionnaire （SAQ） E inclu- ding physical limitation （PL）, angina stability （AS）, angina frequency （AF）, treatment satisfaction （TS） and disease perception （DP）] were observed. Their coagulation function [including prothrombin time （PT）, activated partial thromboplastin time （AP-I-I）, thrombin time （TT）, fibrinogen （FIB）], hs-CRP level and MPO level were simultaneously examined. Results Compared with before treatment in the same group, the scores of PL, AS, AF, TS, and DP all increased, the levels of FIB, hs-CRP and MPO decreased in each group after treatment （all P 〈 0.05）. PT, APTT, and TT were also extended in varying degrees, but the difference was not statistically significant （P 〉0.05）. Compared with the control group at the same time point, the scores of PL, AS, AF, TS, and DP of group A, B and C all improved after treatment （P 〈0.05）. The levels of FIB, blood hs-CRP, and MPO of the three groups declined （P 〈0.05）, with group C being bet- ter than group A and B in this respect （P 〈0.05）. Conclusion QSYQP combined with XTP could improve the PCI patient＇s quality of life, enhance their coagulation function, and lower the levels of the inflammatory factors （hs-CRP, MPO）.

关 键 词：芪参益气滴丸 心脉通贴散 经皮冠脉介入治疗术后 超敏-C反应蛋白 髓过氧化物酶 

分 类 号：R541.4[医药卫生—心血管疾病]